Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712720 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
A Phase 2 study, sponsored by Rezolute.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT05712720: Completed Phase 2 study, sponsored by Rezolute.
NCT05712720 is a Phase 2 study that has completed, run by Rezolute. The registered enrollment target is 94 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05712720, a Phase 2 study, has completed, sponsored by Rezolute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
Primary Outcome
Change from baseline in Central Subfield Thickness (CST), as measured by Spectral Domain Ocular Coherence Tomography (SD-OCT), compared to placebo. Refer to Study Eye Inclusion/Exclusion Criteria for Study Eye definition. Only one eye was chosen as the Study Eye. In the event both eyes were eligible, the eye with the worse edema (greater CST value) was considered for the purpose of this study as the Study Eye. If both eyes had the same level of edema, the right eye was selected.
Interventions
- DRUG Experimental: Group 1 - 50mg RZ402
- DRUG Experimental: Group 2 - 200mg RZ402
- DRUG Experimental: Group 3 - 400mg RZ402
- OTHER Placebo: Group 4 - Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 2 |
What the finished NCT05712720 record still lists
NCT05712720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 4 interventions - of which Experimental: Group 1 - 50mg RZ402 is the first listed.
NCT05712720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05712720 about?
NCT05712720 is a clinical study titled "Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)". The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
What is the current status of trial NCT05712720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2023-02-06. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05712720?
The interventions under investigation include: Experimental: Group 1 - 50mg RZ402 (DRUG), Experimental: Group 2 - 200mg RZ402 (DRUG), Experimental: Group 3 - 400mg RZ402 (DRUG), Placebo: Group 4 - Placebo (OTHER).
Who is sponsoring clinical trial NCT05712720?
This trial is sponsored by Rezolute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05712720's enrollment target sits among peer trials
94 764th of 2000 higher than 1,235 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI